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CHAPTER 1 
Preface 
 
GPCR Research in Drug Discovery 
 G protein-coupled receptors (GPCRs), also known as seven-transmembrane (7-TM) 
receptors, are one of the largest families of membrane proteins. GPCRs sense 
extracellular stimuli (bioactive peptides, including extracellular hormones and 
neurotransmitters, nucleic acids, pH, etc.) and induce various cellular responses by 
activating intracellular signal pathways.  
 
 GPCR signals are transmitted through a trimeric protein called G protein, which 
consists of three subunits, G, G, and G. When a ligand binds to a GPCR, it causes 
conformational changes to the GPCR and the consequent activation of its associated 
G protein by exchanging GDP for GTP. Together with the bound GTP, the α subunit 
dissociates from the β and γ subunits and activates intracellular signal pathways 
depending on the subtype of the α unit. Dissociated GTP-bound Gα as well as β and γ 
subunits modulate various effector functions, and following spontaneous hydrolysis of 
GTP to GDP result in reassociation of GDP-bound Gα with Gβγ. 
 
The functional diversity of the G protein mediated signaling depends on the fact that 
there are numerous subtypes of G proteins. The basic characteristics of the 
heterotrimeric G protein are regulated by the subtype of the α-subunit, which is 
divided into four families: Gαq/Gα11, Gαi/Gαo, Gαs, and Gα12/Gα13.  
 
Although there are many exceptions, the receptor-G protein combinations are 
classified into three basic classes that define the intercellular responses caused by the 
ligand-dependent receptor activation (Figure 1) (Ref. 1). 
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Figure 2. Marketed small-molecule drug targets by biochemical class [modified 
from reference 6] 
 
Figure 2 shows the distribution of biochemical class of marketed drugs. Enzymes 
represent about half of the launched targets, whereas GPCRs account for 30%. All 
other classes, such as ion channels and transporters, accounts for less than a quarter 
of the launch target. 
 
 From the second half of the 1980s, the rush for discovery in GPCR research began 
with homology searches employing the genomic sequence and structural prediction 
(Ref. 8). As genetic information was clarified by the Human Genome Project, over 800 
GPCRs were discovered by bioinformatics analysis (Ref. 9). On the other hand, GPCRs 
found by homology screening suffer from one obvious problem; these receptors are 
orphan receptors lacking information on their endogenous ligands (Ref. 10). 
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Ligand Fishing 
 Owing to the successful mapping of the human genome, the genes of approximately 
350 nonolfactory GPCRs have been cloned. More than 100 GPCRs still remain as 
orphan receptors, for which the endogenous ligands are unknown (Ref. 9, 11). Moreover, 
discovering the agonists and antagonists for those GPCRs is important to drug 
discovery since more than 30% of all marketed drugs are targeting GPCRs (Ref. 6). 
Therefore, the identification of endogenous ligands of orphan GPCRs likely will 
promote the discovery of novel mechanisms of physiological function and new drug 
targets. 
 
There are two approaches to researching target molecules: a reverse type and a 
forward type. In other words, to conduct research to explain phenomena from 
characteristics of the active compounds (forward type, classical approach), or to 
conduct research with known (or predicted to be) disease-related molecules as a 
starting point (reverse type) (Ref. 10). In this reverse pharmacology, the identification 
of a receptor sequence is followed by the corresponding ligand discovery. Physiological 
and pharmacological functions are subsequently examined, for example, using gene 
knockout or overexpression of the receptor. GPCR is a molecular target representing 
this reverse pharmacology approach. 
 
 Ligand fishing is one of the approaches for de-orphanization, which is the process to 
identify a natural ligand for an orphan GPCR. The first orphan GPCR that was used 
for de-orphanization was an opioid receptor-like one, identified by homology search 
with the opioid receptors (Ref. 12). Since then, novel peptides such as ghrelin, 
prolactin-releasing peptide, neuropeptides, prokineticins, and neuromedin S have been 
reported as natural ligands of orphan GPCRs. These successes showed the 
effectiveness of the approach to find novel ligands of orphan GPCRs. Therefore, the 
pharmaceutical industry has rushed into the ligand fishing race. 
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GPR142 
 GPR142 is a G-protein-coupled receptor (GPCR), identified through genome database 
mining as a class A (rhodopsin) G protein-coupled receptor (Ref. 13). Over-expression of 
mouse GPR142 in HEK293 and CHO-K1 cells was shown to lead to activation of NFAT 
and accumulation of inositol phosphate, suggesting that this GPCR is likely coupled to 
Gαq. GPR142 highly expressed in the pancreas and the immune system shares 50% 
amino acid identity with GPR139. Recently, ligands for GPR139, a GPR142-related 
receptor with 50% amino acid identity, were reported as the essential amino acids 
L-Tryptophan (Trp) and L-Phenylalanine (Phe) (Ref. 14). GPR142 was also found to be 
a receptor for aromatic amino acids, with Trp representing one of the most potent 
ligands with an EC50 value of 0.2mM to 1 mM (Ref. 15). 
 
 GPR139 has been relatively more well-studied than GPR142. In humans and mice, 
GPR139 is expressed specifically in distinct areas of the CNS, especially in the basal 
ganglia and the hypothalamus, which are involved in movement control, regulation of 
food intake and metabolism (Ref. 16, 17). To date, four groups have reported small 
molecule ligands for GPR139. GPR139 agonists were shown to reduce locomotor 
activity in rats and protect primary dopaminergic midbrain neurons against some 
neurotoxin (Ref. 18), suggesting GPR139 could be a potential target for treatment of 
Parkinson's disease. 
 
 A high expression level of GPR142 in pancreatic -cells suggests that the receptor 
may play a role in the pathogenesis and development of diabetes. GPR142 is highly 
expressed in pancreatic islets, and Trp and its small molecule agonists (Figure 3) 
stimulated glucose-stimulated insulin secretion (GSIS) in the cultured islets as well as 
in the rodent in vivo model is dependent on GPR142 (Ref. 19)(Figure 4). In addition, 
GPR142 is expressed in intestine and stimulates Trp induced secretion of incretins 
glucagon, like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). 
 F
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 On the other hand, GPR142 is highly expressed in immune cells as well as in 
pancreatic -cells. In addition, the ligand of GPR142, Trp, and its metabolites, 
serotonin and kynurenine, are known to play important roles in inflammation (Ref. 20, 
21), suggesting the receptor may play a role in inflammatory diseases. 
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Chronic Inflammatory Diseases 
 Inflammation, one of the important physiological defense mechanisms against 
infections such as viruses or bacteria, is a biological reaction essential to maintaining 
the healthy state. However, once inflammation comes to be chronic, it sometimes leads 
to the development of intractable diseases, such as autoimmune diseases; as a result, 
chronic inflammation has been recognized as a difficult disease group. In recent years, 
inflammatory diseases, including autoimmune diseases, have shown an increasing 
trend. This is due to rapid changes in the external environment, such as increases of 
stress, complex pollution or change of diet (Ref. 22).  
 
 Symptomatic treatment to block the overall inflammatory response using 
immunosuppressive drugs, including steroids, rather than definitive treatment to 
eliminate the cause of the chronic inflammation is still used in modern medical 
treatment. At the acute advanced stage, symptomatic treatment might be effective, but 
long-term administration can cause serious side effects, leading to a significant 
decrease of the health-related quality of life (QoL) of patients suffering autoimmune 
diseases. Thus, specific therapies based on molecular targets for autoimmune diseases 
are considerably expected to be developed. 
 
 Rheumatoid arthritis (RA) is a systemic and long-lasting autoimmune disease. It is 
reported that RA affects 0.5～1% of adults and ～50 per 100,000 people newly 
developing the condition each year (Ref. 23, 24). Although the cause of RA is not clear, 
it is thought that the combination of environmental and genetic background is 
involved. The underlying mechanism is the attacking of the joints by the auto immune 
system. This results in inflammation and thickening of the joint capsule and damage 
to bone and cartilage. 
 
 In developing RA, the abnormal growth of synovial membrane occurs in rheumatoid 
synovial tissue, while at the same time small blood vessels are formed in joints and the 
immune cells flow in from the blood. These immune cells secrete inflammatory 
mediators such as interleukin and prostaglandin, which are inflammatory cytokines; 
this leads to extensive angiogenesis and production of enzymes, such as matrix 
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metalloproteinases (MMPs) that cause tissue damage. On the other hand, in concert 
with the disease progression, neutrophil flows into the joint tissue and RA-specific 
inflammatory granulation tissue at the edges of the synovial lining (pannus) is formed 
(Ref. 25–28).  
 
 In the pathogenesis of RA, TNF- plays a major role, but there still are many reports 
that other cytokines and chemical mediators are involved in inflammation in RA (Ref. 
29–31). In RA patients, a deleterious cycle can occur where immune cells in the 
inflammatory joint capsule, both leucocyte-derived and lymphocyte-derived, are 
stimulated by cytokines, which leads to the production of more inflammatory cytokines, 
and results in an acute fulminant inflammatory reaction (Ref. 32).  
10 
 
Mouse Models of Chronic Inflammatory Diseases 
 Based on the method of induction, systemically induced mouse models of RA can be 
divided into 3 groups: those elicited by active immunization, those elicited by passive 
immunization, and those elicited by administration (Ref. 33). 
 
 Collagen-induced arthritis (CIA) is the archetypical model of RA induced by active 
immunization. Mice develop an acute to sub-acute single-phase erodible polyarthritis 
after immunization with collagen II. Type II collagen is the major collagen component 
in articular cartilage, and immuno-reactivity to type II collagen can be observed in 
some RA patients (Ref. 34). Many important features of human RA are recapitulated in 
mouse CIA, including the presence of rheumatoid factor or anticitrullinated peptide 
antibody (Ref. 35). A Th17-driven response is reported to be essential for the 
production of lesions (Ref. 36, 37). The effects of interferon  are divergent with 
inhibitory as well as stimulatory effects on development of disease. Overall, however, 
interferon  attenuates  CIA (Ref. 38). 
 
 A widely used example of arthritis induced by passive immunization is the direct 
derivative of CIA, collagen antibody-induced arthritis (CAIA) (Ref. 39, 40). 
One particular benefit of CAIA over CIA is that the model is amenable for use in 
strains or genotypes not suitable for CIA (Ref. 41, 42). CAIA, in contrast to CIA, is a 
fast model (peak disease within 8 days) and has a high degree of synchronicity in 
disease onset. CAIA requires immune complex formation and complement activation, 
but induction of arthritis is B-cell and T-cell independent and does therefore not 
recapitulate the complexity of immune and tissue remodeling responses during human 
RA (Ref. 43). 
 
 CIA mouse models are the most widely used disease models, which recapitulate the 
whole process of RA. CIA require CD4+T-cells for the full induction of arthritis (Ref. 44) 
In contrast, T-cells or B-cells are not required for the induction of CAIA(Ref. 9) since T- 
and B-cell-deficient mice can induce CAIA effectively. 
The contribution of inflammatory cytokines differs depending on the mouse disease 
condition used for evaluation (Table 1). It is indicated that CD4+T-cells are required for 
11 
 
the initiation phase of CIA. CD4+T-cells are not strictly necessary after the production 
of arthritogenic autoantibodies. The severity in the CAIA were augmented by adoptive 
transfer of a CD4+T-cell(Ref. 43). It is important to choose the suitable disease model to 
evaluate the compound efficacy and to understand the underlying mechanism. 
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Table 1. The contribution of proinflammatory cytokines and lymphocytes to the 
development of mouse models of RA [modified from reference 40] 
 
  
IL-17A IL-6 IL-1 TNF CD4+ T-cell B-cell
CIA + + ++ + + +
CAIA NR - ++ ++ - -
IL-1Ra-deficient ++ - NR ++ + -
TNF-Tg NR - ++ ++ - -
-,Not required; +,partially required; ++,substantially required; NR, not reported.
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Summary of the Thesis 
 In Chapter 2, I will discuss the GPR142 endogenous ligand fishing from porcine brain. 
I found an agonistic activity against GPR142 in extract of porcine brain, discriminated 
from L-Tryptophan, previously reported as a GPR142 natural ligand. Thus, I started 
fractionation of the extract to identify the compound that causes the agonistic activity. 
 Ion peak patterns observed in the mass spectrum of the active fraction, as well as 
HPLC retention time and UV spectrum of the active fraction were identical to those of 
standard ZnCl2. From the analysis of the agonistic profile of the active fraction and 
ZnCl2, it was concluded that the agonistic activity against GPR142 observed in porcine 
brain extract was caused by zinc ion. Further analysis revealed that zinc acts not as a 
ligand (agonist), but as modulator, which changes the properties of receptor activation 
by both natural and surrogate ligands. 
 
 In Chapter 3, to elucidate the physiological function of GPR142 especially in immune 
systems, we used GPR142 KO mice to pursue the possibility of GPR142 as a 
therapeutic target for inflammation diseases. GPR142 KO mice were protected from 
anti-type II collagen (CII) antibody-induced arthritis, thus we hypothesized that 
GPR142 could be a potential target for rheumatoid arthritis (RA) treatment.  
 Through an HTS campaign using an aequorin assay, a GPR142 selective antagonist 
with moderate potency, CLP-3094 was identified from in-house small molecule 
chemical compound libraries. Administration of CLP-3094 to CAIA mice 
dose-dependently reduced, by not much, the arthritis scores. CLP-3094-treated mice 
consistently displayed significantly lower severity of arthritis scores than vehicle 
treated mice, suggesting that the receptor also may play a role in the immune system. 
 
 In Chapter 4, this is described in the Concluding Remarks. 
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CHAPTER 2 
GPR142 Endogenous Ligand Fishing From Porcine Brain 
 
Abstract 
In a search for endogenous ligands for GPR142, a neutral amino acid L-Tryptophan 
(Trp) was reported as a possible endogenous ligand from collaboration partner Amgen. 
On the other hand, I found an agonistic activity against GPR142 in extract of porcine 
brain, discriminated from Trp. Thus, I started fractionation of the extract to identify 
the compound that causes the agonistic activity. 
A partially purified active fraction was obtained by a series of chromatography. The 
following two results indicated the presence of zinc ion in the active fraction. First, ion 
peak patterns observed in the mass spectrum of the active fraction were quite similar 
to the isotope peak pattern of Zn. Second, HPLC retention time and UV spectrum of 
the active fraction were identical to those of standard ZnCl2. ZnCl2 (EC50 = 1.4 µg/mL 
[10 µM]) and the active fraction (EC50 = 3 µg/mL) induced inositol phosphate (IP) 
accumulation at the similar concentration ranges in DMEM medium, and those 
accumulations were inhibited by adding EDTA. Therefore, it was concluded that the 
agonistic activity against GPR142 observed in porcine brain extract was caused by zinc 
ions.  
Further analysis of the characteristics of zinc ions’ activity against GPR142 
activation was carried out more in more detail. First, I compared the effect of other 
metal ions on activation against GPR142. MnCl2 and AlCl3 also showed the agonistic 
activity, but both of them were weak compared to ZnCl2. 
Interestingly, zinc showed agonistic activity by inositol phosphates accumulation 
assay (IP assay) using cultured media as assay buffer, but not Hanks HEPES (H/H) 
buffer, meanwhile Trp showed both with the media and H/H buffer. Further analysis 
revealed that zinc acts not as a ligand (agonist), but as a modulator, which changes the 
properties of receptor activation by both natural and surrogate ligands. 
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Introduction 
GPR142 is an orphan G-protein coupled receptor (GPCR), whose ligand has not yet 
been reported and thus its biological function is not clear. To identify a natural ligand 
for an orphan GPCR is important to clarify its physiological activity, and also to 
identify a novel target for drug discovery (Ref. 45). Discovery of ghrelin, a peptide 
ligand for growth hormone secretagogues receptor (GHS-R) purified from stomach (Ref. 
46), accelerated the race for searching for the ligands (so-called ligand fishing) for 
orphan GPCRs. 
GPR142 study started as a collaboration work with Amgen. Amgen reported Trp 
was purified from abdominal dropsy as a possible endogenous ligand for GPR142. 
However, its efficacy was very low (EC50 = 100 µg/mL). On the other hand, I found an 
agonistic activity against GPR142 in extract of porcine brain, discriminated from Trp. 
Furthermore, preliminary study for partially purified active fraction showed that the 
EC50 for the product was about 4 µg/mL, even stronger compared to the EC50 for Trp. 
Consequently, I decided to start the purification of active product from porcine brain to 
identify a novel natural ligand for GPR142. 
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Materials and Methods 
Preparation of GPR142 cDNA and Expression in mammalian cell 
Human GPR142 (hGPR142) receptor cDNA was cloned from a human spleen cDNA 
library and its sequence was confirmed (UniGene 1847355 - Hs.574368). The 
respective amplified fragment was subcloned into the pcDNA3.1 expression vector. 
Human embryonic kidney 293 (HEK293) cells were grown in DMEM supplemented 
with 10% FBS and penicillin-streptomycin. HEK293 cells were transfected with 
hGPR142 plasmid using Lipofectamine 2000 reagent (Invitrogen: Thermo Fisher 
Scientific Inc. Waltham, MA, USA). 
 
Inositol Phosphates Accumulation Assay (IP Assay) 
HEK293 cells were maintained in DMEM supplemented with 10% FBS and 
penicillin-streptomycin at 37 °C under a condition of 5% CO2. Inositol phosphate 
accumulation was assayed as the incorporation of 3H-myo-inositol as described (Ref. 
47). Briefly, HEK293 cells were transiently transfected with human or mouse GPR142 
containing plasmid using Lipofectamine 2000 reagent (Thermo Fisher Scientific Inc. 
(Waltham, MA, USA) and plated on culture plates the day previous to the assay. One 
day after transfection, cells were incubated over night with 10 Ci of 
myo-[3H(G)]-inositol (PerkinElmer, Inc., Waltham, MA, USA) in 10 mL of inositol free 
medium supplemented with 10% fetal bovine serum. Cells were stimulated with 
compounds in the presence of 10 mM LiCl for 90 min at 37 °C using cultured media 
(DMEM) as assay buffer before the addition of 20 mM ice-cold formic acid for 
extraction followed by incubation on ice for 30 min. The generated [3H]-inositol 
phosphate was detected using RNA Binding YSi SPA Scintillation Beads (by 
interacting with primary phosphate groups in nucleotides and oligonucleotides, DNA 
and RNA.) (PerkinElmer, Inc., Waltham, MA, USA). 
 
Aequorin Assay 
 The aequorin assay was performed as previously described (Ref. 48). Briefly, 
CHO-K1 cells were co-transfected with plasmids expressing pro-aequorin and mouse 
or human GPR142. Twenty-four hours later, transfected cells were harvested and 
incubated with Hank’s balanced salt solution (HBSS, Gibco: Thermo Fisher Scientific 
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Inc. Waltham, MA, USA) containing 0.1% BSA (Sigma-Aldrich, St. Louis, MO, USA), 
and 1 g/mL coelenterazine h (Molecular Probes: Thermo Fisher Scientific Inc. 
Waltham, MA, USA) for 2 h to 4 h. Aequorin luminescence was measured using an 
FDSS6000 (Hamamatsu Photonics K.K., Hamamatsu, Japan). 
 
Preparation of the Extracts From Porcine Brain 
Porcine brain (average size: 100 g per portion) purchased from Tokyo Shibaura 
Zouki K.K. was processed on the day of butchery or stored in the freezer at -20 °C. 
Three portions of the brain were put in a Waring® Blender with 700 mL of 50 mM 
ammonium formate (pH 7.0). After 1 minute blending, samples were cooled on ice for 
10 min and centrifuged (4,700g, 10 min, 4°C). Collected supernatant was added to 3 
times the volume of methanol and mixed to leave at 4°C overnight. The next day, the 
mixture was centrifuged (4,700g, 10 min, 4°C), and the supernatant was concentrated 
using a rotary evaporator to remove methanol from the extract. Finally, the 
concentrate was subject to freeze-drying to obtain the porcine brain extract sample for 
ligand fishing. The dark brown extract sample obtained from 300 g (3 portions) porcine 
brain was about 4.2 g. 
 
Purification of active fraction from porcine brain extracts 
The procedure for purification of the agonistic component against GPR142 from 
porcine brain extract sample is shown in Figure 1. 
The extract sample (70 g) from 5 kg brain was dissolved in D.W. and formic acid was 
added until the sample reached to pH 3.0. The supernatant was collected after 
centrifugation (2,000g, 15 min, 4°C). 
A Diaion Sepabeads SP 207 column (500 mL) was equilibrated with 10 mM 
ammonium formate (pH 3.0, buffer-A), and the supernatant was loaded into the 
column and maintained for 8 h under a 4°C condition. The column was washed by 4.5 L 
of buffer-A. The flow-through and wash fractions were combined to 9 L and prepared to 
pH 9.0 with aqueous ammonia. Another Diaion Sepabeads SP 207 column (the second 
column, 500 mL) was equilibrated with 10 mM ammonium formate (pH 9.0, buffer-B), 
and the combined flow-through and wash fraction was loaded into the second column 
and maintained for 9 hours under a 4°C condition. The second column was washed by 3 
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L of buffer-B. Then, the second column was equilibrated to room temperature and 
adsorbed components in the column were desorbed by 3 L of buffer-A containing 10% 
acetone. The eluent was concentrated using a rotary evaporator to remove acetone and 
was then subjected to freeze-drying. A dark brown oily sample (126.2 mg) was obtained. 
This oily sample (70 mg) was diluted with 40 mL of 100 mM sodium acetate (pH 5.0, 
buffer-C), and the diluted sample was loaded into the 10 mL of Sigma-Aldrich CM 
Sephadex C-25 column equilibrated with buffer-C. The column was washed with 40 
mL of buffer-C, 80 mL of buffer-C supplemented with 0.5 M NaCl and 80 mL of 
buffer-C supplemented with 1.0 M NaCl sequentially. Adsorbed components in the 
column were desorbed by 80 mL of buffer-C supplemented with 2.0 M NaCl to give 
Active Fraction 1 (EC50 = 3 µg/mL against GPR142). 
 
The buffers used for the fractionation were prepared as follows: 
Buffer-A: 380 µL (10 mmol) of ammonium formate was added to 1000 mL D.W. and 
prepared to pH 3.0 with 28% aqueous ammonia. 
Buffer-B: 676 µL (10 mmol) of 28% aqueous ammonia was added to 1000 mL D.W. 
and prepared to pH 9.0 with formic acid. 
Buffer-C: 100 mM aqueous acetic acid and 100 mM sodium acetate was mixed in the 
ratio of 14.8:35.2 and prepared to pH 5.0. 
 
Removal of Trp, Phe and Tyr, GPR142 Possible Endogenous Ligands From Porcine 
Brain Extracts 
The Sepabeads SP 207 elution fraction (Figure 1) was subjected to weakly acidic 
cation exchange chromatography. The elution fraction was loaded into the 10 mL 
Sigma-Aldrich Amberlite CG-50 column equilibrated with D.W. The column was 
washed with 40 mL of D.W. and then adsorbed components on the column were 
desorbed by following 80 mL of 0.1 N HCl and subject to the analysis by LC/MS to 
check the removal of Trp, Phe and Tyr. 
 
Stability of the Activity in the Active Fraction 
The above 0.1 N HCl eluted fraction from the weakly acidic cation exchanger 
Amberlite CG-50 was used for the tests. 
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Ten micro liters of buffer-A, D.W. or buffer-B was added to 40 L of the eluted 
solution. Each sample was heated for 30 min at 60°C (Sample AH, NH or BH) or 120 
min at 40°C (Sample AL, NL or BL). After heat treatment, each sample was 
freeze-dried once, and re-dissolved for the testing of GPR142 agonistic activity. 
 
Molecular Size Estimation on Electrodialysis 
HCl (0.1 N) eluted fraction (500 L) from the weakly acidic cation exchanger 
Amberlite CG-50 (same as used for Stability Test) was electrodialyzed by using 
"Microacilyzer G1", a portable desalting apparatus commercialized by SUNACTIS Co., 
Ltd., Osaka, Japan, equipped with an AC-110 (for Mw cut 100) or AC-220 (for Mw cut 
300) comprising a cation-exchange membrane and an anion-exchange membrane, both 
of which have a molecular weight cut-off of about 100 or 300. An amount of 0.5 M 
NaNO3 solution (25 mL) was used as an electrode solution and final electric current 
was set to 0.02 A. 
 
LC/MS-MS Analysis 
LC/MS analysis was performed on an Agilent 1100 LS/MSD system. The HPLC 
column was a Capcellpak AQ (4.6 x 150 mm, Shiseido Co., Ltd.). Separation was 
accomplished with the mobile phase containing solvents A and B in gradient, where A 
was 0.1% heptafluorobutyric acid (HFBA) (v/v) in water and B was 0.1% HFBA (v/v) in 
90% acetonitrile (v/v). The linear gradient time program was from 0% to 18% B in 15 
min. The flow rate was 1.0 mL/min. The UV data were obtained with a photodiode 
array detector for the wavelengths from 190 nm to 400 nm and the profiles at 210 nm 
were extracted. A mass spectrometric detector was operated under positive ion mode 
and the scanned m/z range was from 50 to 500. The ESI interface and mass 
spectrometer parameters were optimized to obtain maximum sensitivity. 
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Results and Discussion 
Characterization of an active component from porcine brain extract 
Before starting the purification of an active component from porcine brain extract, 
heat and pH stability tests and molecular size estimation of the active component was 
performed. 
Agonistic activity of the extract was stable both in acidic and basic conditions as 
well as neutral (60°C, 30 min and 40°C, 120 min, Figure 2A) and also stable at pH 1 
and 13 (r.t., 2 h) (data not shown). 
 
To exclude the possibility that the active component was a small molecule salt, 
desalination from the porcine brain extract sample using an electorodialyzer 
(microacilyzer) was performed. Electrodialysis is a technology to separate ionic 
substances in aqueous solution, which utilizing electrophoresis and ion exchange 
membranes. This technology enables efficient concentration, desalination, refining and 
recovery. There are two types of membranes. Anion exchange membranes allow anion 
permeation selectively and cation exchange membranes allow cation permeation. A 
large number of these membranes are placed alternately between two electrodes and 
apply direct current to separate ions in solution as shown in Figure 2B. Formula 
weight of the active component was estimated to be between 100 and 300 from the 
electrodialysis experiment (Figure 2C). Thus, I decided to try the basic procedures 
used to purify small basic compounds for the identification of the active component(s) 
in this porcine brain extract. 
 
Moreover, polar basic character is inferred from ion-exchange and reversed-phase 
chromatographs. 
 Chromatographic behavior of the agonistic activity on HPLCs 
-Reversed phase column (modified octadecyl-bonded silica [ODS]  
 or octadecyl-bonded polymer [ODP]) 
 Acidic: No retention (pH 3.7, pH 5.5 and 0.04% TFA) 
 Neutral: Broad elution (pH 6.4) 
 Basic: No elution (pH 9.0) 
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-Gel filtration column (polyvinyl alcohol) 
 Good elution (neutral, 50 mM ammonium formate) 
 
-Normal phase column (silica) 
  Good elution (CH3CN/50 mM ammonium-formate pH 3, gradient) 
In addition, high concentration of ammonium formate is necessary for good elution, 
but that causes high background ions in LC/MS analysis. 
 
Identification of an Active Component From Porcine Brain Extract 
 The neutral amino acids L-Tryptophan (Trp) and Phenylalanine (Phe) have been 
reported as possible endogenous ligands from our collaboration partner Amgen. Thus, 
before starting to explain the identification of the active component from porcine brain 
extracts, I thought it necessary to confirm that the active component(s) was not either 
of these neutral amino acids. 
 The procedure for purification of the agonistic component against GPR142 from 
porcine brain extract samples is shown in Figure 1. Sepabeads SP 207 elution fraction 
(Figure 1) was subject to weak cation exchange chromatography in an acidic condition. 
The agonistic activity against GPR142 was eluted in the HCl fraction with a high 
recovery rate (EC50 = 5 ~ 10 g/mL). Removal of Trp (EC50 = 100 g/mL), Phe and Tyr 
from the eluted sample was confirmed by LC/MS analysis, thus the active 
component(s) was discriminated from these neutral amino acids. 
 
LC/UV-MS profiles of the Active Fraction 1 from porcine brain extracts are shown 
in Figure 3. The agonistic activity against GPR142 were observed in the fraction 
corresponded to the peak from 9.1 min to 9.5 min as the retention time (Active Fraction 
2). Several ion peaks with the peak pattern of 2 mass unit intervals were observed in 
the mass spectrum of Active Fr. 2 (Figure 4) throughout the retention time. The 
isotope peak pattern of Zn (64Zn, 100%; 66Zn, 57.4%; 67Zn, 8.4%; 68Zn, 38.7%; 70Zn, 1.3%) 
was found to have similar 2 mass unit intervals in the MS spectrum after searching for 
these characteristic peak patterns of Active Fr. 2. Therefore I hypothesized that the 
active component in porcine brain extract may be any compound containing zinc. 
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Representative UV chromatograms of the reference standard ZnCl2 and the Active 
Fr. 1 are shown in Figure 5. A similar peak was observed around 9 min, and identity of 
retention time and UV spectrum of both samples indicated the presence of a zinc ion in 
Active Fr. 1. 
 
Thus, I hypothesized that the zinc ion may play an important role in the activation 
of GPR142. The activity of the reference standard ZnCl2 and Active Fr. 1 were 
compared using IP assay in some conditions (Figure 6). ZnCl2 (EC50 = 1.4 µg/mL 
[10 µM]) and Active Fr. 1 (EC50 = 3 µg/mL) showed almost the same efficacy against 
GPR142. Furthermore, these activities were both inhibited by adding EDTA. 
 
I concluded that the active component in porcine brain was zinc ion. The 
preliminary results of electrodialysis experiments showed that formula weight of the 
active component was estimated to be between 100 and 300. However, the molecular 
weight of zinc is 65.38. The anionic and cationic membranes used for dialysis are 
essentially made from anionic and cationic exchange resins respectively. These resins 
have mentioned to have a typical selectivity depending on ions for analysis; e.g., the 
higher the charge of the ion, the stronger it interacts with the resin. For transport 
through a cationic or anionic exchange membrane, multivalent ions (like zinc as 
divalent ion) may be more strongly retained in the membrane material and thus 
thought to be transported more slowly(Ref. 49, 50) and retained in AC-110 (for Mw cut 
100). 
 
It is reported that Zn also acts on GPR39 (Ref. 51) and GPR83 (Ref. 52) as an 
endogenous agonist. The serum concentration of zinc was reported as being about 
100 µg/dL (15 µM) (Ref. 53), which is enough to show biological activity against 
GPR142 in vivo. GPR142 is highly expressed in pancreatic beta cells and the immune 
system, suggesting the receptor may play the role in the control of diabetes or 
inflammation diseases (Ref. 54). In collaboration research with Amgen, several 
GPR142 agonists were discovered and they are shown to be possible insulin 
secretagogues (Ref. 15). At the molecular and cellular level, zinc (Zn) is known to be 
involved in insulin synthesis, secretion and signaling, and thus, the consequent actions 
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of insulin on metabolism (Ref. 55, 56). Mechanisms of GPR142 activation by zinc are 
still not clear, but GPR142 may play some role in insulin secretion in vivo and zinc also 
play an important role in insulin signaling, and the known effect of zinc to protect Type 
2 diabetes may be partly from GPR142 activation. 
 
Zinc Ion Acts on GPR142 as a Modulator, Not as an Agonist Itself 
Zinc ion was found to have the agonistic activity against GPR142 in porcine brain 
extract. It has been reported that essential metals, Fe, Zn, Co, Ni and Mn act on OGR1 
as endogenous agonists (Ref. 57). Moreover, there are some reports that metal ions 
such as Na＋, Ca2＋, Mg2＋ act as allosteric modulators which activate GPCRs only with 
their ligands (Ref. 58, 59). 
 
There are many reports that have suggested the modification of GPCR by Zn2＋.  
Zn2＋ has been reported as a positive allosteric modulator of agonist binding for the 
2-AR (Ref. 60). It was reported that the binding of either an agonist or an antagonist 
to serotonin receptor 1A (5HT1A-R) were prevented completely by zinc (Ref. 61). D1 
and D2 dopamine receptors do not lose all ligand binding properties in the presence of 
zinc, like 5HT1A-R, but they do have decreased affinity for ligands (Ref. 62). This led 
me to assume that the observed GPR142 activation by zinc might be resulted from 
modulating the affinity of its ligand, Trp but not by direct activation of the receptor.  
 
The zinc ions in an inositol phosphates accumulation assay (IP assay) showed 
agonistic activity using cultured media as an assay buffer, but not Hanks HEPES 
(H/H) buffer; meanwhile, Trp showed agonistic activity both with the media and H/H 
buffer (Figure 7). These data were consistent with my hypothesis that zinc ions act not 
as a ligand (agonist), but as a modulator, which changes the properties of receptor 
activation by both natural and surrogate ligands. It is assumed that zinc ions do not 
act as an agonist individually, but show agonistic activity by enhancing the agonistic 
activity of Trp contained in DMEM. In other words, the presence of Trp is necessary for 
the activity induced by zinc ions. At the same time, the enhancement of the IPs 
accumulation by zinc, but not by Trp was inhibited by adding EDTA, suggesting that 
Trp can activate GPR142 directly without the presence of zinc ions. 
24 
 
During the purification of zinc from porcine brain extract, I used cultured media 
(DMEM) as an assay buffer for the IPs accumulation testing. The composition of 
DMEM (Thermo Fisher Scientific, Cat. No.: 11965) is shown in Table 1. DMEM 
contains 78.4 M of Trp and 400 M of Phe, since Trp is an essential amino acid for 
survival. Since the EC50 of Trp for human GPR142 is 500 M and that of Phe is still 
higher, Trp and Phe contained in the DMEM were not enough to fully activate the 
receptor. I hypothesized that zinc in porcine brain extract may modulate (increase) the 
affinity of Trp and Phe in DMEM, which induced the enhanced accumulation of 
secondary signal molecules. 
 
For the further confirmation that zinc ions enhance the agonistic activity of Trp 
against GPR142, enhancement of IPs accumulation by zinc ions in various GPR142 
agonists was tested. The reported GPR142 agonists, Trp and Phe as possible 
endogenous ligands and phenylalanine derivative as a synthetic small molecule 
agonist were used to test the enhancement of IPs accumulation by zinc ion. As shown 
in Figure 8, zinc modulated (increased) the affinity of not only Trp, but all of the tested 
compounds. 
 
Finally, to confirm the possibility that other metal ions that may be contained in 
Active Fr. 2 also have agonistic activity against GPR142, I compared the effect of other 
metal ions on activation against GPR142 (Figure 9). Only MnCl2 and AlCl3 showed the 
same modulator activity as ZnCl2, but both of them were weak compared to ZnCl2. 
CuSO4 showed agonistic activity only in Hanks/HEPES buffer but not in dose 
dependent manner. It may necessary to further analyze the activity of CuSO4 
regarding GPR142. 
  
25 
 
 
 
Figure 1. A schematic way of purification of the GPR142 active component(s) from 
porcine brain 
 
  
Basic fraction of the extract from Porcine brain 5 kg 
↓absorpƟon chromatography (Sepabeads SP 207) 
↓weak caƟon exchange chromatography in an acidic condiƟon 
     (CM Sephadex C-25) 
2M NaCl eluted fr.    
     ⇒Active fr.1 (EC
50
 = 3g/ml) 
↓ion pair chromatography (ODS, HFBA) 
LC/UV-MS analysis; Peak at 9 minutes   
     ⇒Active fr.2 
  
(A)
 
  
26 
 
 (B) 
 
 
 
 
 
 
 
 
(C) 
F
(A) S
(Sam
treat
GPR
contr
data 
stand
Elect
poten
estim
elect
100, 
agon
igure 2. 
tability of 
ples AH, N
ment, each
142 agonis
ol with D.W
are presen
ard devia
rodialysis 
tial differe
ation in 
rodialysis u
each samp
istic activit
Character
the active 
H or BH)
 sample w
tic activity
. and non
ted as mea
tion show
(ED) is a 
nce as a d
electrodial
sing a mem
le was free
y at the ind
ization of an
component
 or 120 mi
as freeze-
 at the in
-treat was 
ns of %act
n as erro
membrane
riving force
ysis of th
brane that
ze-dried o
icated con
27 
 active com
(s). Each s
n at 40°C 
dried once
dicated co
sample free
ivation fro
r bars. (B
 separatio
 for movin
e active 
 limits com
nce, and re
centration 
ponent from
ample was 
(Samples A
, and re-di
ncentration
ze-dried w
m quadrup
) The pr
n process 
g ions in so
componen
ponent mo
-dissolved 
(v/w). 
 porcine b
heated for 
L, NL or 
ssolved for
 (v/w). BG
ithout heat
licate mea
inciple of 
that utiliz
lutions. (C
t in the 
lecular size
for the tes
rain extract 
30 min at 
BL). After
 the testi
 was neg
 treatment
surements
electrodia
es an elec
) Molecula
fraction. 
 to under 3
ting of GP
 
60°C 
 heat 
ng of 
ative 
. The 
 with 
lysis. 
trical 
r size 
After 
00 or 
R142 
  
 
(A) 
(B) 
(C) 
 
28 
 
 
 
 
 
 
 
 
 
 
29 
 
 
 
 
Figure 3. LC/UV-MS Profiles of the Active Fraction 1 from porcine brain extracts 
Column: Capcellpak AQ 4.6 x 150 mm; flow rate: 1 mL/ min; eluent: CH3CN / H2O - 
0.1% HFBA gradient (0% -15 min - 18% CH3CN). (A) UV chromatogram at 210 nm. (B) 
Total ion chromatogram (TIC) with electrospray ionization in positive ion mode; a 
full-scan mass spectrum covering the m/z range 50-500. (C) UV spectrum of Active Fr. 
2 (9.2 min spectrum, as reference spectra at 9.0 min and 9.7 min). (D) MS spectrum of 
Active Fr. 2 (additional spectra from 9.1 min to 9.5 min, as reference spectra at 9.0 min 
and 9.7 min). 
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Figure 9. Enhancement of IPs accumulation of GPR142 expressing cells by 
various metal salts 
 HEK293 cells transiently expressing human GPR142 were incubated with various 
metal salts at the indicated concentrations (M in order) for 90 min at 37°C using H/H 
Buffer or cultured media (DMEM) as an assay buffer. The data are presented as mean 
CPM values readouts from MicroBeta (Perkin Elmer). 
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Table 1. The composition of DMEM and Hanks/HEPES Buffer used as assay 
buffer 
 
The composition of DMEM and Hanks/Hepes Buffer were shown in Table 1. The 
components highlighted in grey were GPR142 active compounds. 
DMEM Hanks HEPES buffer
mg/L Mw Conc.(M) mg/L
CaCl2 200 CaCl2 140
Fe(NO3)/9H2O 0.1
KCl 400 KCl 400
KH2PO4 60
MgSO4 97.67
MgCl2/6H2O 100
MgSO4/7H2O 100
NaCl 6400 NaCl 8000
NaHCO3 3700
NaH2PO4 125
NaH2PO4/7H2O 90
D-Glucose 4500 D-Glucose 1000
Phenol Red 15
HEPES -5958 20 mM HEPES
Pyruvic acid -110
Arg 84
Cys/2HCl 63
Gln -584
His HCl/H2O 42
Ile 105
Leu 105
Lys HCl 146
Met 30
Phe 66 165.19 4.00E-04
Ser 42
Thr 95
Trp 16 204 7.84E-05
Tyr 2Na/2H2O 104 181.19 5.74E-04
Val 94
D-Ca Pantothenate 4
Choline Chloride 4
Folic acid 4
inositol 7.2
Niacinamide 4
Riboflavin 0.4
Thiamine HCl 4
Pyridoxine HCl 4
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CHAPTER 3 
Discovery and Pharmacological Effects of a Novel GPR142 Antagonist 
 
Abstract 
In Chapter 2, I found an agonistic activity against GPR142 in extract of porcine 
brain, discriminated from L-Tryptophan (Trp) and concluded that the agonistic 
activity against GPR142 observed in porcine brain extract was caused by zinc ion.  
 GPR142 is highly expressed in pancreatic -cells and immune cells, suggesting the 
receptor may play a role in the pathogenesis and development of diabetes or 
inflammatory diseases. In a previous scientific report (Ref. 15), our project team 
developed GPR142 agonists as insulin secretagogues. 
 In this chapter, I show the discovery of a selective, potent small-molecule GPR142 
antagonist, CLP-3094, and its pharmacological characteristics. These data support 
targeting this receptor for the treatment of chronic inflammatory diseases. 
 
Introduction 
 GPR142 is a GPCR highly expressed in the pancreas and the immune system, and 
shares 33% amino acid identity with GPR139 (Ref. 17). Recently, ligands for GPR139 
were reported as being the essential amino acids Trp and L-Phenylalanine (Phe) (Ref. 
14). GPR142 was also found to be a receptor of aromatic amino acids with Trp 
representing one of the most potent ligands, having an EC50 value of 0.2 mM to 1 mM 
(Ref. 15). 
 The high expression level of GPR142 in pancreatic -cells suggests that the receptor 
may play a role in the pathogenesis and development of diabetes. In our previous 
research, we reported the discovery of novel GPR142 agonists as insulin secretagogues. 
GPR142 is highly expressed in pancreatic islets and Trp triggered glucose-stimulated 
insulin secretion (GSIS) in the cultured islets as well as in a rodent in vivo model 
dependent on GPR142 (Ref. 19). In addition, GPR142 is expressed in intestine, and Trp 
induced incretin secretion of glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic peptide (GIP) is also dependent on GPR142. Thus, our findings provide a 
novel mechanism for glucose homeostasis and may lead to new strategies for diabetes 
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treatment.  
 On the other hand, GPR142 is highly expressed in immune cells as well as in 
pancreatic -cells. In addition, the ligands of GPR142, Trp and its metabolites, 
serotonin and kynurenine, are known to play important roles in inflammation (Ref. 20, 
21). In order to clarify the function of GPR142 in the immune system, I used GPR142 
KO mice to pursue the possibility of GPR142 as a therapeutic target for inflammation 
diseases. GPR142 KO mice were protected from anti-type II collagen (CII) 
antibody-induced arthritis, thus I hypothesized that GPR142 could be a potential 
target for rheumatoid arthritis (RA) treatment.  
 In this chapter, I present the first reporting of a pharmacological characterization of a 
selective, potent small-molecule GPR142 antagonist. The data provided herein 
supports targeting this receptor for the treatment of chronic inflammatory diseases. 
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Materials and Methods 
Materials 
 An arthritogenic monoclonal antibody (mAb) cocktail was purchased from 
Immuno-Biological Laboratories (Gunma, Japan) and LPS was purchased from 
Calbiochem through Merck Millipore (Darmstadt, Germany). Bovine type II collagen 
(CII) was purchased from Collagen Research Center (Tokyo, Japan). Complete Freund 
Adjuvant (CFA) was purchased from Becton, Dickinson and Company (Franklin Lakes, 
NJ, USA). ELISA kits for IL-1 and TNF-were purchased from R&D Systems. Inc. 
(Minneapolis, MN, USA). TRIzol reagent and TaqMan Universal PCR Master Mix, 
TaqMan Reverse Transcription Reagent, TaqMan Rodent GAPDH Control Reagent, 
and TaqMan Probes were purchased from Thermo Fisher Scientific Inc. (Waltham, MA, 
USA).Midazolam was purchased from Wako Pure Chemical Industries, Ltd. 
-nicotinamide adenine dinucleotide phosphate sodium salt (-NADP), and D-glucose 
6-phosphate were purchased from Sigma-Aldrich (St. Louis, MO, USA). Glucose- 
6-phosphate dehydrogenase was purchased from Oriental Yeast Co., Ltd. (Tokyo, 
Japan) 
 All other reagents and solvents including DMSO (dimethylsulfoxide) and Tween 80 
(Polyoxyethylenesorbitan Monooleate) used in this study were of either HPLC or 
analytical grade. 
 
Animals 
 BALB/cAnNCrj (BALB/c) mice were purchased from Charles River (Tokyo, Japan). 
C57BL/6J Jcl mice were secured from CLEA Japan (Tokyo, Japan). GPR142-deficient 
mice were generated by Lexicon Pharmaceuticals, Inc. (The Woodlands, TX, USA). KO 
mice used for this study were backcrossed with C57BL/6 mice for at least 6 generations. 
All mice were purchased from the ages of 5 weeks to 6 weeks, and housed at 
Daiichi-Sankyo Laboratories (Tokyo, Japan), and given a standard rodent chow diet 
and water ad libitum. All Experimental procedures were performed in accordance with 
the in-house guideline of the Institutional Animal Care and Use Committee of Daiichi 
Sankyo. 
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Calcium Transient Assay (HTS format; Fluo-3) 
 The Calcium Transient Assay was performed as previously described (Ref. 63). 
Briefly, CHO-K1 stably expressing human GPR142 was plated in a 384-well microplate 
with 14,000 cells per well using Trp depleted DMEM supplemented with 10% dialyzed 
FBS and 1% Pen/Strep. 24 hours later, the media was discarded (dumped) from the cell 
plate and Fluo-3 AM with quencher dye with Hank’s balanced salt solution (HBSS, 
Gibco: Thermo Fisher Scientific Inc., Waltham, MA, USA) containing 0.1% BSA 
(Sigma-Aldrich, St. Louis, MO, USA), 20 mM HEPES (pH 7.4) was added to the cells. 
The cells were then incubated for 1 h before adding the testing compounds for the 
screening. After 20 minutes, fluorescence intensity change was measured by adding 
Trp as the ligand, and by using a FLIPR TETRA (Molecular Devices, LLC., Sunnyvale, 
CA, USA). 
 
Inositol Phosphate Formation Assay (HTS format; HTRF IP One Assay) 
 Inositol phosphate accumulation was measured using an IP-One HTRF® assay kit 
purchased from Cisbio K.K. The HTRF assay was performed in accordance with the 
manufacturer’s instruction manual. Briefly, HEK293 cells were transiently transfected 
with human GPR142 containing plasmid using Lipofectamine 2000 reagent (Thermo 
Fisher Scientific Inc., Waltham, MA, USA) and plated in a culture plate on the 
previous day of the assay. Cells were stimulated with analytes for 90 min at 37 °C 
using stimulation buffer before the addition of detection reagents. 
 
Calculations 
 IC50 and EC50 values were calculated using nonlinear regression curve fitting using 
GraphPad Prism (Graphpad Software, Inc., San Diego, CA, USA). The basal 
constitutive activity is expressed as a percentage of the mock transfected (pcDNA 
control vector) cells’ activation. 
 
Induction of Anti-Type II Collagen Antibody-Induced Arthritis (CAIA) 
 CAIA was induced by the method of Terato et al. (Ref. 64, 65) using an arthritogenic 
mAb cocktail. For the induction of arthritis, GPR142 KO or wild type (C57BL/6) 
littermates were injected in to the tail intravenously with 2 mg per mouse of anti-CII 
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antibody, and 3 days later 100 μg of LPS (Escherichia coli 0111:B4) was 
intraperitoneally injected. Hind paws of each mice were examined for any swelling as 
described previously (Ref. 66). The severity of arthritis was graded on a 0 to 3 scale as 
follows: 0 = normal, 1 = swelling of one digit, 2 = swelling of two or more digits and 3 = 
swelling of entire paw. 
 
Induction of Collagen-Induced Arthritis (CIA) 
 On the day of the injection, 100 μg bovine CII was dissolved in 100 μL acetic acid 
(0.05 mol/L) and mixed with an equal volume of CFA until emulsified. Each of the 
anesthetized Female DBA1/J mice (aged 6 weeks) was immunized intradermally near 
the base of the tail with the emulsified solution on Day 0 and 7 or 21. 
 
Induction of Dextran Sulfate Sodium (DSS)-Induced Colitis 
 Eight female C57BL/6N mice (aged 9 weeks) were randomized into a control group 
and DSS treated group. Colitis was induced by means of drinking water supplemented 
with 3% DSS (45,000–50,000 m.w.; MP Biomedicals, Santa Ana, CA), as described 
previously (Ref. 67). Control mice were treated in a same way with drinking water 
without DSS.  
 
Treatment of Mice with CLP-3094 
 Twenty-four Female DBA1/J mice (aged 6 weeks) were randomized into a control 
group and a CLP-3094 treated group. CLP-3094 was i.p. injected into mice at a dose of 
30 or 100 mg per mouse (based on its pharmacokinetic profile in this species) after LPS 
injection for 8 days. As a control, an equal volume of sterile vehicle 
(DMF/tween80/saline = 10:10:80) was injected into mice (Vehicle group). 
 
Measurement of Blood Cytokine, L-Tryptophan and Kynurenine Levels 
 LPS (1 mg/kg) or anti-CII antibody cocktail (2 mg per mouse) was injected into 
GPR142 KO or wild type (C57BL/6J) mice intravenously. After 1 or 4 hours, 
respectively, venous blood was collected from anesthetized mice and centrifuged for 5 
min at 13,230 g and supernatant was collected to obtain plasma. The concentrations of 
IL-1 and TNF- in plasma were measured using ELISA kit following to the 
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manufacturer’s instructions of each kit. The concentrations of Trp and kynurenine 
were measured by HPLC as previously described (Ref. 68). 
 
GPR142 m-RNA Expression Levels in CIA Mice (RT-PCR) 
 Quantitative real-time PCR (RT-PCR) was performed using ABI Prism 7700 System 
(Thermo Fisher Scientific Inc.) to analyze the level of chemokine and cytokine mRNAs 
by the development of arthritis, following the manufacturer’s instructions. Briefly, on 
Day 0 and 7 or 21, rear footpads were collected from arthritis induced mice after 5 or 
7 weeks from the 1st immunization. Total RNA was extracted soon after the collections 
from the pooled footpads using TRIzol reagent. Using random 9-mers, 1 μg of total 
RNA was transcribed with TaqMan reverse transcription reagents for cDNA synthesis. 
TaqMan probes and primers were designed using Primer Express(Thermo Fisher 
Scientific Inc.), except for GAPDH. The following mouse gene-specific primers were 
used for amplification: GPR142 (UniGene 1847355 - Hs.574368) forward 
5’-gtcttcgtcatgctctaccac-3’, reverse 5’-ctgtgatgccaaagtgcagg-3’. TaqMan probes were 
labeled at the 3’ end with the quencher dye TAMRA and at the 5’ end with the reporter 
dye, FAM, except for GAPDH, labeled with VIC. cDNA samples  were mixed with 
primers and TaqMan Universal PCR Master Mix as described in the manufacturer’s 
instructions. The PCR was performed using the following parameters: 50°C for 2 min, 
95°C for 10 min, and 40 cycles at 95°C for 15 s and 60°C for 1 min. RT-PCR was 
performed for TNF-and IL-1β and normalized with the GAPDH mRNA copy number 
from the same sample. Acquired data were analyzed using SDS Software version 1.63 
(Thermo Fisher Scientific Inc.). 
 
In vitro metabolic stability, solubility and plasma protein binding ratio of CLP-3094 
 In vitro metabolic stabilities were measured using rat or mouse liver S9 fractions. 
The residual rates of CLP-3094 and midazolam (as a positive control) were determined 
after incubation with liver S9 fraction (10 mg/mL) and NADPH generation systems 
(2.5 mM -NADP, 10 mM MgCl2, 25 mM D-glucose 6-phosphate, and 2 units/mL 
 of glucose-6-phosphate dehydrogenase) for 5, 15 or 30 minutes. Solubility studies 
were performed using JP (Japanese Pharmacopoeia)-1 (pH 1.2) or JP-2 (pH 6.8). 
Percent protein binding to mouse plasma was determined by the ultracentrifugation 
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method. The concentrations of the drug in each assays were measured using a Liquid 
Chromatography - tandem Mass Spectrometry (MicroMass®, Nihon Waters K.K.) 
(Generic method). 
 
Pharmacokinetics study of CLP-3094 
 CLP-3094 was administered intravenously (0.5 mg/10 mL/kg) or orally (2.5 mg/20 
mL/kg as the solution in DMSO/Tween 80/saline (10/10/80, v/v/v) or 2.5 mg/20 mL/kg 
as the suspension in 0.5% methylcellulose solution) to mice (male, C57BL/6J (Charles 
River Laboratories Japan, Inc.), 8 weeks, N=3, Fed). The blood was collected with 
heparin treated syringes and the plasma samples were prepared by the centrifugation 
for the measurement of CLP-3094 . CLP-3094 concentrations in the plasma were 
determined using a Liquid Chromatography - tandem Mass Spectrometry (API4000®, 
Thermo Fisher Scientific K.K.) (Generic method). PK parameters (total clearance (CL), 
distribution volume (V), area under the curve (AUCinf), maximum concentration 
(Cmax) and oral bioavailability (BA)) were calculated using the computer software 
Phoenix WinNonlin (Ver. 6.3., Certara USA, Inc.). 
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Results and Discussion 
Induction of CAIA in GPR142 Knock Out (KO) Mice 
 First, as generally done, I analyzed mRNA expression levels of GPR142 in human and 
mouse tissues. GPR142 showed a broad expression in many tissues tested, but 
relatively high expression levels in the spleen and lymph nodes as well as the pancreas 
(data not shown). Based on the expression in immune tissues, I hypothesized that 
GPR142 may play a role in the control of inflammatory diseases, and planned to induce 
CAIA using GPR142 KO mice to analyze the potential of GPR142 as a therapeutic 
target. 
 GPR142 KO mice, both female and male, showed reduced arthritis scores and disease 
incidence against CAIA (Figure 10). Protection was observed using both the subjective 
visual score or by the objective measurement of paw swelling. This is the first report 
that GPR142 KO mice were resistant to CAIA induction compared to wild type mice. 
 Significant reduction in the severity of DSS-induced colitis in GPR142 KO mice was 
also confirmed by evaluation of body weight loss and colon shortening (data not shown). 
These data strongly suggest that GPR142 could be a potential target for treatment of 
inflammatory diseases. 
 
Blood Cytokine Levels in GPR142 KO Mice Treated with LPS or Anti-CII Antibody 
 In order to better help understand how GPR142 is involved in the development of 
CAIA, I measured the levels of inflammatory cytokines, TNF- and IL-1β, after 
treatment of LPS or anti-CII antibody (Figure 11). Production of TNF- was relatively 
reduced in GPR142 KO mice compared to wild type (C57BL/6) littermates in both the 
treated with LPS group and the treated with anti-CII antibody group; however, 
production of IL-1β was reduced by LPS, but not by anti-CII antibody. These data 
showed the decreased production of inflammatory cytokines might partly explain how 
GPR142 deficiency caused the resistance to CAIA. 
 
GPR142 Expression and Blood Trp Concentrations in Collagen-Induced Arthritis (CIA) 
Mice and Dextran Sulfate Sodium (DSS)-Induced Colitis Mice 
 I examined the mRNA expression of GPR142 in a CIA model in mice, another mouse 
model of rheumatoid arthritis. Mice were immunized intradermally on Day 0 and 7 or 
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21 with 100 μg bovine CII mixed with an equal volume of CFA until emulsified. After 5 
or 7 weeks from the 1st immunization, swelling paws from the CIA mice were 
homogenated and GPR142 mRNA levels were quantified by real-time RT-PCR. mRNA 
expression of GPR142 in swelling paws from the CIA mice was relatively higher, but 
not significantly higher than that of vehicle treated mice (Figure 12A). At the same 
time points of the experiment, the GPR142 natural ligand, Trp, concentrations in sera 
from the CIA mice were reduced and its metabolites, collectively called kynurenines, 
and known as inflammatory mediators, were increased (Figure 12B). Similar 
tendencies were observed in DSS-induced colitis mice (Figure 13). These results 
suggested there being an increased degradation of Trp in CIA and DSS colitis mice. 
 Furthermore, Trp degradation was observed as being lower in GPR142 KO mice 
than in wild type mice (Figure 14). 
 
Establishment of Biochemical Assays for the Screening of GPR142 Antagonist 
 For the GPR142 antagonist screening campaign, I first established the 384-well plate 
calcium transient assay. Changing to the culture media using Trp depleted DMEM and 
dialyzed FBS the night before the assay was essential to obtaining a sufficient GPR142 signal 
since DMEM contains 78.4 M of Trp and 400 M of Phe and these amino acids activate the 
receptor weakly but continuously, which leads to the de-sensitization of the receptor. 
Overnight depletion of Trp is needed to recover the receptor fully from de-sensitization. 
 To evaluate the quality of the calcium transient assay, the Z’ factor value was 
calculated using the following equation (Ref. 69). 
Z’ factor ＝ 1-(3σhigh + 3σlow)/(Avhigh-Avlow) 
 SD: Standard Deviation, Av: Average 
 high: High control, low: Low control 
 The Z’ factor is a general tool for the validation and evaluation of any bioassay in 
general and in particular, for assays for High Throughput Screening(HTS). The Z’ 
factor value for the calcium transient assay for human GPR142 antagonist screening 
from data of Figure 15 was 0.63 with limited numbers (n = 16) of positive (high, 1 mM 
Trp) and negative (low, no Trp) controls. In general, It is considered that when the Z’ 
value is greater than 0.50, the assay is considered to be of high quality and to be 
suitable for HTS.  
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 Next, I setup the 384-well plate IP-One HTRF® assay for GPR142 antagonist 
screening. In Chapter 2, I used radio-labeled 3H-myo-inositol to measure the inositol 
phosphate accumulation subsequent to the activation of the receptor. But this protocol 
was complicated and expensive, and moreover the usage of radio-labeled materials for 
the screening was troublesome. The IP-One HTRF® assay described here offers a 
simple, sensitive, cost-effective, and homogeneous screening method for seeking 
GPR142 antagonists. Another advantage of inositol phosphate accumulation 
measurement is that this method is generally thought to be more sensitive compared 
to the calcium transient assay. The calcium transient assay can quickly measure 
(transient) activation of the receptor within a few minutes (usually 1-3 minutes), on 
the other hand the IP-One HTRF® assay measures the accumulation of inositol 
phosphates within 90 minutes in accordance with the increase of intercellular calcium 
concentration. Very weak, undetectable levels of increase in intercellular calcium ions 
can cause (trigger) inositol phosphate formation, and the accumulation can be 
detectable with a relatively long time period. 
 
Identification of CLP-3094, a GPR142 Specific Antagonist 
 Through a high throughput screening (HTS) campaign, I identified several GPR142 
antagonists with moderate potency, including Serotonin (5-HT1D) selective agonist, 
NOT (5-(nonyloxy)tryptamine) (Figure 16A). Serotonin is one of the structurally 
related metabolites of Trp. Serotonin itself did not have any effect on GPR142, neither 
did any other serotonin agonists or antagonists tested, except for NOT. Antagonist 
activity of NOT was relatively weak, the IC50 value was 3 M against 200 M Trp for 
the mouse receptor (data not shown). 
 The compound of greatest potential obtained was CLP-3094, a benzimidazol class of 
compound (Figure 16B). CLP-3094 inhibited both an increase of intracellular Ca2+ 
concentration ([Ca2+]i) induced by Trp using CHO-K1 cells expressing GPR142 in the 
aequorin assay, and an accumulation of inositol phosphates using HEK293 cells 
expressing GPR142 in a SPA assay. The IC50 value of CLP-3094 was 0.2 M (Table 2) 
against 200 M Trp for the mouse receptor and 2.3 M against 1 mM Trp for the 
human receptor in the aequorin assay. CLP-3094 also inhibited the insulin secretion 
from islets induced by both Trp and GPR142 agonists (data not shown). CLP-3094 
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demonstrated itself to be a highly GPR142 specific antagonist, showing no inhibitory 
activity either for the serotonin receptor or the other tested GPCRs (Ghrelin, CCR4, 
CCK1), but showed itself to have about a 10 times weaker, partial antagonistic activity 
(~30% maximum inhibition) against the closely related GPCR, GPR139 (Table 2). 
 
CLP-3094 Worked Also as an Inverse Agonist 
 Heterologous expressions of GPCRs have sometimes been result in the induction of 
ligand-independent signal in an essentially linear fashion with increasing levels of 
GPCR expression (Ref. 70). Milligan et al. demonstrated that the constitutive activity 
of GPCR was not associated with the presence of endogenous agonists, and many 
traditional ‘antagonists’ were shown to have the ability to block these constitutive 
activity of expressing GPCRs. These compounds have been reclassified as inverse 
agonists (Ref. 71). 
 Overexpression of mouse GPR142 in HEK293 cells led to an increase in inositol 
phosphate accumulation, compared to mock transfected cells (Figure 17). However, 
human GPR142 showed the same level of inositol phosphate accumulation as the 
control mock transfected in HBSS containing 20 mM HEPES and 0.1% BSA (H/H 
buffer), suggesting high constitutive activity in mouse receptors, but not in human 
ones. CLP-3094 inhibited this constitutive activity of mouse GPR142 (in H/H buffer), 
but showed no inhibition against human GPR142, which suggested it’s being in a basal 
state. On the other hand, when using cultured media (DMEM + 10% FBS) as an assay 
buffer, human GPR142 also showed the increase of accumulation caused by Trp and 
Phe contained in DMEM and in serum. Though the reported serum concentration of 
Trp was about 13 g/mL (65 µM) (Ref. 72), which is not enough to show full biological 
activity against GPR142 in vivo, GPR142 may be constitutively activated in vivo, and 
CLP-3094 could inhibit both mouse and human GPR142 to the basal levels. 
 These data suggest that CLP-3094 worked not only as an antagonist, but also as an 
inverse agonist against GPR142. This inverse agonist profile of CLP-3094 was also 
confirmed in an NFAT Luciferase assay (data not shown). 
 
Effect of CLP-3094 on CAIA Mice 
 Next, to assess the therapeutic potential of GPR142 inhibition by CLP-3094, I 
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assessed the efficacy of CLP-3094 in the CAIA mouse model. Mice were i.v. 
administered 2 mg of anti-collagen antibody, followed by i.p. administration of 50 g of 
LPS. CLP-3094 was i.p. administered at doses of 30 or 100 mg/kg daily from Day 0 to 
Day 11. Swelling of the paws was examined daily after LPS injection. Disease severity 
was assessed periodically, and clinical signs of disease were scored. 
 The severity of arthritis was scored and plotted as shown in Figure 18. The results 
showed that administration of CLP-3094 dose-dependently reduced, by not much, the 
arthritis scores. CLP-3094-treated mice consistently displayed significantly lower 
severity of arthritis scores than vehicle treated mice (p = 0.03 by repeated measures 
1-way ANCOVA test). 
 
Pharmacokinetics of CLP-3094 
 The results of in vitro metabolic stability study, solubility study and protein binding 
study were shown in Table 3. CLP-3094 was much less stable than midazolam after the 
incubation with rat or mice liver S9 fraction. CLP-3094 showed high solubility in JP-1 
but not in JP-2. The plasma protein binding ratio of CLP-3094 was very high (over 
99%) and therefore it means that the free fraction of this compound in the plasma is 
very low (less than 1% of the plasma concentration). 
 The mouse PK profiles and PK parameters after intravenous or oral administration of 
CLP-3094 were determined and shown in Fig. 19 and Table 4. Total clearance (CL) , 
distribution volume (Vd) and t1/2 in the plasma of this compound were 48.9±6.9 
mL/min/kg, 0.981±0.261 L/kg and 0.740±0.363 h, respectively. The oral bioavailability 
(BA) of solution or suspension was 35.5±43.5% or 6.35±1.36%, respectively. 
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To elucidate the physiological function of GPR142 especially in immune systems, I 
aimed to identify selective compounds for GPR142. Through an HTS campaign using 
an aequorin assay, I identified a GPR142 selective antagonist with moderate potency, 
CLP-3094. The administration of CLP-3094 dose-dependently reduced the arthritis 
scores, but not by much. One of the reasons explaining this insufficient effect of 
CLP-3094 on inhibition of CAIA could be the in vivo rapid clearance of CLP-3094 itself 
(T1/2 = 1.71 h). Since the IC50 of CLP-3094 is sub-micromolar, an efficacious 
concentration may not be maintained well enough to show a sufficient inhibition. The 
PK profiles of CLP-3094 might be able to explain its insufficient in vivo efficacy.  
 There is also a concern that the effect of CLP-3094 on CAIA is produced not only 
through GPR142, but partially via the closely related GPCR, GPR139, since CLP-3094 
had weak antagonistic activity against GPR139 in the in vitro aequorin assay. Both 
GPR142 and GPR139 share the same ligands, the essential amino acids Trp and Phe. 
But GPR139 is exclusively expressed in the central nervous system (CNS) (Ref. 16, 17) 
and in situ hybridization experiments in mouse brain showed that GPR139 mRNA is 
abundantly expressed in the septum, caudate, habenula, zona incerta, and medial 
mammillary nucleus. In addition, Trp and its metabolites, serotonin, and kynurenine, 
are widely known to play an important role in CNS disease (Ref. 73, 74). It is 
considerable that GPR139 is mainly expressed in CNS and plays specific roles in the 
modulation of brain functions, while on the other hand, GPR142 is mainly expressed in 
immune cells and in the controlling of inflammatory diseases, with the exception being 
its expression in pancreatic -cells. There are two reports on discoveries of GPR139 
antagonists (Ref. 75, 76), but the pharmacological functions of these antagonists have 
not yet been reported. I am anticipating this future research. 
 The CAIA model is an excellent system for studying human rheumatoid arthritis, as 
it requires only a few weeks to receive the results (Table 5). The modulation of 
pro-inflammatory cytokines, such as TNF-α, IL-1β and IL-12, using either small 
molecule inhibitors or biologics is crucial to control rheumatoid arthritis, and many 
trials are still in progress to demonstrate this concept (Ref. 77-79). CAIA requires 
immune complex formation and complement activation, but induction of arthritis in 
this model is B cell and T cell independent and does therefore not recapitulate the 
complexity of immune and tissue remodeling responses during human rheumatoid 
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arthritis (Ref. 80). The reduced sensitivity of GPR142 KO mice to CAIA suggested that 
involvement of GPR142 in development of arthritis is B cell and T cell independent. 
 I also used another mouse arthritis model, CIA, for the further analysis of the 
function of GPR142. The messenger RNA expression level of GPR142 was higher in 
CIA mice compared to control CFA mice. At the same time point of the disease, Trp 
degradation increased. A similar tendency was observed in DSS-induced colitis, a 
model of human Crohn’s disease. The DSS-induced colitis model is a little more 
complicated. Inflammatory bowel disease is characterized by sustained intestinal 
mucosa inflammation, which is mainly caused by excessive macrophage activation and 
Th1 and/or Th17 immune responses. Oral DSS activates intestinal macrophages, 
leading to massive production of inflammatory cytokines and chemokines. 
Subsequently, a number of lymphocytes are recruited to the inflamed sites, resulting in 
Th1 and Th17 responses. 
 The degradation of Trp generates neuroactive metabolites, kynurenines, and the 
kynurenine pathway is under the tight control of inflammatory mediators (Ref. 73). It 
is a well-known mechanism that GPCRs become desensitized when exposed to their 
ligand for a prolonged period of time (Ref. 81). The hypothesis that increased 
production of inflammatory cytokines might accelerate the degradation of Trp, which 
decreases the desensitization of GPR142, corresponds reasonably well with the 
experimental data. But, further examination of GPR142 remains before truly 
understanding how GPR142 is involved in the development of CAIA or CIA, as well as 
DSS colitis. 
 In a previous paper, we reported the development of novel GPR142 agonists as potent 
insulin secretagogues. In this chapter, I showed that a GPR142 antagonist reduced the 
severity of CAIA in a mouse model, suggesting the receptor also may play a role in the 
immune system. To develop GPR142 agonists or antagonists as clinical drugs, I should 
work in a more determined way to clarify how GPR142 is involved in inflammatory 
diseases; and I will always need to follow both concurrently, from the standpoint of 
assessing side-effects dependent upon the relationship between agonists and 
antagonists. 
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Figure 10. GPR142 deficiency reduces sensitivity to CAIA in mice 
 Wild type group (n = 5) and GPR142 knock out group (n = 8), 10-week old mice were 
treated via i.v. on Day 0 with 2 mg anti-CII antibody and subsequently boosted with 
100 g of LPS on Day 3 to induce collagen induced antibody arthritis. Arthritis score 
(A) and incidence (B) are shown as mean (S.E.M.) in different groups of GPR142 knock 
out and wild type (C57Bl/6) littermates. Closed circle: GPR142+/+ (Wild type) mice; 
Open circle: GPR142–/– (GPR142 KO) mice. *P < 0.05, **P < 0.001 
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Table 2. Selectivity of antagonist activity of CLP-3094. 
 
 
 
 Summary of antagonist pharmacology (IC50) of CLP-3094 determined in intracellular 
aequorin assay or GTPs binding assay. A GTPs binding assay was performed using 
membrane purchased from Euroscreen S.A., and following the manufacturer’s 
instructions. Briefly, membranes were incubated with 35S labeled GTPγ and 
compounds at room temperature for 60 minutes. Then, suspended WGA SPA beads (1 
mg/well) were added, and the plates were sealed and incubated for more than one hour 
at room temperature. They were then centrifuged at 200 g and plate luminescence was 
measured in a Wallac Microbeta® Trilux. 
  
GPCR GPR142* GPR139* GHSR* CCR4* MT1** 5-HT1**
Ligand L-Tryptophan Surrogate
Agonist
Ghrelin MDC / CCL22 Melatonin Serotonin
IC50 0.2 M 1.67 M N.D. N.D. >50 M >50 M
Efficacy 100% 30% N.D. N.D. N.D. N.D.
*N.D. = Not Determined
*Aequorin assay using stable cell line
**GTPs binding assay using cell membrane
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Table 3. In vitro metabolic stability, solubility and plasma protein binding ratio of 
CLP-3094 
 
 
A) Metabolic stability
Protein concentration Protein Reaction time Residual rates (%) Midazolam residual rates (%)
1.0 mg/mL Rat-S9 5 min 26.8 69.3
1.0 mg/mL Rat-S9 15 min 2.2 50.5
1.0 mg/mL Rat-S9 30 min 1.2 34.7
1.0 mg/mL Mouse-S9 5 min 0.4 53.4
B) Solubility
Solution  Solubility (
JP1 >100.0
JP2 0.7
C) Plasma protein binding
Protein Source Protein Type Binding (%) Free(%)
Mouse-Plasma C57BL/6J 99.76 0.24
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Table 4. PK parameters after intravenous or oral administration of CLP-3094 to 
mice 
 
 
  
iv (0.5 mg/kg, solution (DMSO/Tween80/Saline =10/10/80))
Parameters Mean SD
AUC0-inf (μM*h) 0.567 0.078
t1/2 (h) 0.74 0.363
CL (mL/min/kg) 48.9 6.9
Vss (L/kg) 0.981 0.261
po (2.5 mg/kg, solution (DMSO/Tween80/Saline =10/10/80))
Parameters Mean SD
Cmax (μM) 0.584 0.426
AUC0-inf (μM*h) 1.01 1.23
tmax (h) 0.25 0.00
t1/2 (h) 1.71 0.47
Bioavailability (%) 35.5 43.5
po (2.5 mg/kg, suspension (0.5%MC))
Parameters Mean SD
Cmax (μM) 0.170 0.011
AUC0-inf (μM*h) 0.180 0.038
tmax (h) 0.25 0.00
t1/2 (h) 1.93 0.30
Bioavailability (%) 6.35 1.36
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Table 5. Comparison of CAIA and CIA model 
 
  
Collagen Antibody-Induced
Arthritis; CAIA Collagen-Induced Arthritis; CIA
Experimental
period 7～14 days 6～8 week
Mouse strain C57BL/6、DBA1、Balb/c、Transgenic、etc DBA/1、C57BL/6
Method of
administration
Intraperitoneal, tail vein
administration
Intradermal administration near the
base of the tail
Arthritis
incidence 100% 60～90%
Arthritis score 10～16 6～12
Arthritis
Induction arthritogenic mAb cocktail、LPS Type II collagen、Adjuvant
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CHAPTER 4 
 
Concluding Remarks 
GPR142, a putative amino acid receptor, is expressed in pancreatic islets and 
immune cells, but the physiological role of this receptor remains unclear. Synthetic 
GPR142 agonists were demonstrated to stimulate glucose-dependent insulin secretion 
and improve glucose tolerance in vivo (15). In the course of finding the GPR142 
endogenous ligand, I found an agonistic activity against GPR142 in extract of porcine 
brain, discriminated from Trp. 
 
 In Chapter 2, I purified the active component(s) from the porcine brain extract to 
identify the compound that causes the agonistic activity against GPR142. From ion 
peak patterns observed in the mass spectrum and the comparison of the activity 
profiles, it was concluded that the agonistic activity against GPR142 observed in 
porcine brain extract was caused by zinc ion. Further analysis revealed that zinc acts 
not as a ligand (agonist), but as a modulator that changes the properties of receptor 
activation by both natural and surrogate ligands. 
 
In Chapter 3, CLP-3094 was found to be a novel, potent, selective GPR142 
antagonist. I also showed the pharmacological characteristics of CLP-3094. GPR142 
KO mice were shown to be protected from anti-type II collagen (CII) antibody-induced 
arthritis and dextran sulfate sodium (DSS)-induced colitis. Administration of 
CLP-3094 reduced the arthritis scores dose-dependently, but not by much. The 
hypothesis that increased production of inflammatory cytokines might accelerate the 
degradation of L-Tryptophan, which decreases the desensitization of GPR142, 
corresponds reasonably well with the experimental data. But, further examination of 
GPR142 remains to be performed before truly understanding how GPR142 is involved 
in regulation of the pathogenesis and development of inflammatory diseases. 
 
It is my hope that this work will contribute to the evolution of drugs for providing 
good medications to patients in the future.  
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